Loading…

The PLA2R1-JAK2 pathway upregulates ERR[alpha] and its mitochondrial program to exert tumor-suppressive action

Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this s...

Full description

Saved in:
Bibliographic Details
Published in:Oncogene 2016-09, Vol.35 (38), p.5033
Main Authors: Griveau, A, Devailly, G, Eberst, L, Navaratnam, N, Le Calvé, B, Ferrand, M, Faull, P, Augert, A, Dante, R, Vanacker, J M, Vindrieux, D, Bernard, D
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Little is known about the biological role of the phospholipase A2 receptor (PLA2R1) transmembrane protein. In recent years, PLA2R1 has been shown to have an important role in regulating tumor-suppressive responses via JAK2 activation, but the underlying mechanisms are largely undeciphered. In this study, we observed that PLA2R1 increases the mitochondrial content, judged by increased levels of numerous mitochondrial proteins, of the mitochondrial structural component cardiolipin, of the mitochondrial DNA content, and of the mitochondrial DNA replication and transcription factor TFAM. This effect of PLA2R1 relies on a transcriptional program controlled by the estrogen-related receptor alpha1 (ERR[alpha]) mitochondrial master regulator. Expression of ERR[alpha] and of its nucleus-encoded mitochondrial targets is upregulated upon PLA2R1 ectopic expression, and this effect is mediated by JAK2. Conversely, downregulation of PLA2R1 decreases the level of ERR[alpha] and of its nucleus-encoded mitochondrial targets. Finally, blocking the ERR[alpha]-controlled mitochondrial program largely inhibits the PLA2R1-induced tumor-suppressive response. Together, our data document ERR[alpha] and its mitochondrial program as downstream effectors of the PLA2R1-JAK2 pathway leading to oncosuppression. Oncogene (2016) 35, 5033-5042; doi: 10.1038/onc.2016.43; published online 4 April 2016
ISSN:0950-9232
1476-5594
DOI:10.1038/onc.2016.43